ASCO 2014: Strong results for Bristol-Myers Yervoy, and combo with nivolumab

2 June 2014

Among the latest important research results presented at the 2014 prestigious annual meeting of the American Society of Clinical Oncology (ASCO) meeting taking place in Chicago, were presentations on US drug major Bristol-Myers Squibb’s (NYSE: BMY) already-marketed Yervoy (ipilimumab) and investigational agent nivolumab, two drugs that have been forecast as achieving potential sales of as much as $7 billion for the company.

Treatment with ipilimumab after surgery reduces melanoma risk recurrence

Results from a large clinical study show that treatment with ipilimumab decreases the risk of melanoma coming back after surgery by roughly 25% for people diagnosed with high-risk stage III disease. However, this treatment causes serious side effects.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK